Adaptive Biotechnologies (ADPT) EV to EBIT (2019 - 2026)

Adaptive Biotechnologies has disclosed EV to EBIT across 8 years of filings, most recently posting 195.01 for Q2 2026.

• In Q2 2026, EV to EBIT fell 209.89% year-over-year to 195.01; the TTM figure through Jun 2026 stood at 82.1 (down 531.1% YoY), while the FY2025 annual figure was 39.85, down 877.64% from the prior year.
• EV to EBIT came in at 195.01 for Q2 2026 at Adaptive Biotechnologies, down from 104.46 in the prior quarter.
• In the past five years, EV to EBIT ranged from a high of 201.13 in Q3 2025 to a low of 195.01 in Q2 2026.
• Average EV to EBIT over 5 years is 28.94, with a median of 14.94 recorded in 2022.
• The largest YoY upside for EV to EBIT was 1381.94% in 2025 against a maximum downside of 1131.66% in 2025.
• Over 5 years, EV to EBIT stood at 15.19 in 2022, then soared by 66.24% to 5.13 in 2023, then tumbled by 281.95% to 19.58 in 2024, then plunged by 810.13% to 178.24 in 2025, then retreated by 9.41% to 195.01 in 2026.
• Per Business Quant data, the three most recent EV to EBIT figures were 195.01 in Q2 2026, 104.46 in Q1 2026, and 178.24 in Q4 2025.